{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T04:45:28Z","timestamp":1782017128265,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"DOI":"10.1007\/s11892-026-01619-4","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:48:15Z","timestamp":1773118095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-5920","authenticated-orcid":false,"given":"Larissa","family":"Ara\u00fajo de Lucena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deivyd V. S.","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela V.","family":"Montenegro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa C.","family":"Hespanhol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Q.","family":"Muniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruti","family":"Prathivadhi-Bhayankaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Kaplinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Barbagelata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7271-4845","authenticated-orcid":false,"given":"Juliana","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"9901","key":"1619_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FGR Fowkes","year":"2013","unstructured":"Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UKA, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 2013;382(9901):1329\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(13)61249-0.","journal-title":"Lancet"},{"issue":"9","key":"1619_CR2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","volume":"116","author":"MH Criqui","year":"2015","unstructured":"Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circul Res. 2015;116(9):1509\u201326. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303849.","journal-title":"Circul Res"},{"issue":"1","key":"1619_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1464-5491.2009.02866.x","volume":"27","author":"EB Jude","year":"2010","unstructured":"Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes\u2014A review. Diabet Med. 2010;27(1):4\u201314. https:\/\/doi.org\/10.1111\/j.1464-5491.2009.02866.x.","journal-title":"Diabet Med"},{"key":"1619_CR4","doi-asserted-by":"publisher","unstructured":"Mah\u00e9 G, Aboyans V, Cosson E, Bernard M, Valensi P, Potier L. Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: A tailored diagnosis and treatment review. Cardiovasc Diabetol. 2024;23(1). https:\/\/doi.org\/10.1186\/s12933-024-02325-9.","DOI":"10.1186\/s12933-024-02325-9"},{"issue":"9","key":"1619_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1161\/CIRCRESAHA.114.303517","volume":"116","author":"MM McDermott","year":"2015","unstructured":"McDermott MM. Lower extremity manifestations of peripheral artery disease: The pathophysiologic and functional implications of leg ischemia. Circul Res. 2015;116(9):1540\u201350. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.303517.","journal-title":"Circul Res"},{"issue":"10193","key":"1619_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryd\u00e9n L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Bosch J. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"19","key":"1619_CR7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Vilsb\u00f8ll T, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"10","key":"1619_CR8","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2337\/dc18-0654","volume":"41","author":"K Dhatariya","year":"2018","unstructured":"Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Torn\u00f8e K, Pratley RE, LEADER Trial Investigators. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial. Diabetes Care. 2018;41(10):2229\u201335. https:\/\/doi.org\/10.2337\/dc18-0654.","journal-title":"Diabetes Care"},{"issue":"20","key":"1619_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David JP, Buse JB, SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2501006.","journal-title":"N Engl J Med"},{"issue":"10489","key":"1619_CR10","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, Rasouli N, Sourij H, Videmark A, Verma S, STRIDE Trial Investigators. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet (London England). 2025;405(10489):1580\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(25)00509-4.","journal-title":"Lancet (London England)"},{"key":"1619_CR11","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372. https:\/\/doi.org\/10.1136\/bmj.n71. Article n71.","DOI":"10.1136\/bmj.n71"},{"key":"1619_CR12","doi-asserted-by":"publisher","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. 2nd ed. Wiley; 2019. pp. 241\u201384. https:\/\/doi.org\/10.1002\/9781119536604.ch10.","DOI":"10.1002\/9781119536604.ch10"},{"key":"1619_CR13","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, Higgins JPT. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. https:\/\/doi.org\/10.1136\/bmj.l4898. Article l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"1619_CR14","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hr\u00f3bjartsson A, Kirkham J, J\u00fcni P, Loke YK, Pigott TD, Higgins JPT. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355. https:\/\/doi.org\/10.1136\/bmj.i4919. Article i4919.","DOI":"10.1136\/bmj.i4919"},{"issue":"4","key":"1619_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/22.4.719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719\u201348. https:\/\/doi.org\/10.1093\/jnci\/22.4.719.","journal-title":"J Natl Cancer Inst"},{"issue":"7414","key":"1619_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"1","key":"1619_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2307\/1267913","volume":"18","author":"RR Corbeil","year":"1976","unstructured":"Corbeil RR, Searle SR. Restricted maximum likelihood (REML) estimation of variance components in the mixed model. Technometrics. 1976;18(1):31\u20138. https:\/\/doi.org\/10.2307\/1267913.","journal-title":"Technometrics"},{"key":"1619_CR18","doi-asserted-by":"publisher","first-page":"112083","DOI":"10.1016\/j.diabres.2025.112083","volume":"222","author":"JY Wu","year":"2025","unstructured":"Wu JY, Tu WL, Yu T, Liao KM, Lin YM. Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients. Diabetes Res Clin Pract. 2025;222:112083. https:\/\/doi.org\/10.1016\/j.diabres.2025.112083.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"1619_CR19","doi-asserted-by":"publisher","first-page":"147916412513229","DOI":"10.1177\/14791641251322909","volume":"22","author":"JE Lewis","year":"2025","unstructured":"Lewis JE, Omenge DK, Patterson AR, Anwaegbu O, Tabukum NN, Lewis JE 3rd, Lee WC. The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study. Diabetes Vasc Dis Res. 2025;22(2):14791641251322909. https:\/\/doi.org\/10.1177\/14791641251322909.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"3","key":"1619_CR20","doi-asserted-by":"publisher","first-page":"e241545","DOI":"10.1001\/jamanetworkopen.2024.1545","volume":"7","author":"P Caruso","year":"2024","unstructured":"Caruso P, Maiorino MI, Longo M, Porcellini C, Matrone R, Digitale Selvaggio L, Gicchino M, Carbone C, Scappaticcio L, Bellastella G, Giugliano D, Esposito K. Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical Trial. JAMA Netw open. 2024;7(3):e241545. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.1545.","journal-title":"JAMA Netw open"},{"issue":"12","key":"1619_CR21","doi-asserted-by":"publisher","first-page":"e008018","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018","volume":"12","author":"A Badjatiya","year":"2019","unstructured":"Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, Pagidipati NJ, Sattar N, Holman RR, Hernandez AF, Mentz RJ, Patel MR, Jones WS. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. Circ Cardiovasc Interv. 2019;12(12):e008018. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.008018.","journal-title":"Circ Cardiovasc Interv"},{"issue":"13","key":"1619_CR22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, \u00d6hman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1612917.","journal-title":"N Engl J Med"},{"issue":"3","key":"1619_CR23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/23969873241230549","volume":"9","author":"MI Stefanou","year":"2024","unstructured":"Stefanou MI, Theodorou A, Malhotra K, Katsanos AH, Ganesh A, Shoamanesh A, Sharma M, Tsivgoulis G, Turc G. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP\/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis. Eur Stroke J. 2024;9(3):530\u20139. https:\/\/doi.org\/10.1177\/23969873241230549.","journal-title":"Eur Stroke J"},{"issue":"5","key":"1619_CR24","doi-asserted-by":"publisher","first-page":"501562","DOI":"10.1016\/j.endien.2024.07.002","volume":"72","author":"F Garagoli","year":"2025","unstructured":"Garagoli F, Masson W, Barbagelata L, Lobo M. Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Endocrinolog\u00eda Diabetes y Nutrici\u00f3n (English Ed). 2025;72(5):501562. https:\/\/doi.org\/10.1016\/j.endien.2024.07.002.","journal-title":"Endocrinolog\u00eda Diabetes y Nutrici\u00f3n (English Ed)"},{"issue":"23","key":"1619_CR25","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1509225.","journal-title":"N Engl J Med"},{"issue":"1","key":"1619_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/XCE.0000000000000142","volume":"7","author":"J Reed","year":"2018","unstructured":"Reed J, Kanamarlapudi V, Bain S. Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. Cardiovasc Endocrinol Metabolism. 2018;7(1):18\u201323. https:\/\/doi.org\/10.1097\/XCE.0000000000000142.","journal-title":"Cardiovasc Endocrinol Metabolism"},{"issue":"24","key":"1619_CR27","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","volume":"146","author":"N Marx","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146(24):1882\u201394. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059595.","journal-title":"Circulation"},{"key":"1619_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2019.07.007","volume":"288","author":"C Anholm","year":"2019","unstructured":"Anholm C, Kumarathurai P, Pedersen LR, Samkani A, Nielsen JR, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A, Haugaard SB. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin-treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Atherosclerosis. 2019;288:60\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.07.007.","journal-title":"Atherosclerosis"}],"updated-by":[{"DOI":"10.1007\/s11892-026-01622-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000}}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-026-01619-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-026-01619-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-026-01619-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:16:11Z","timestamp":1775794571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-026-01619-4"}},"subtitle":["Incretin Therapy in T2DM and PAD"],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1619"],"URL":"https:\/\/doi.org\/10.1007\/s11892-026-01619-4","relation":{},"ISSN":["1539-0829"],"issn-type":[{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the author name from Larissa C. HeAuthorNamehol to Larissa C. Hespanhol.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11892-026-01622-9","URL":"https:\/\/doi.org\/10.1007\/s11892-026-01622-9","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review and meta-analysis utilized data from previously published studies and did not involve primary data collection from human or animal subjects. Consequently, ethical approval was not required. Data were extracted from publicly available sources in accordance with ethical guidelines for secondary data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Studies Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5"}}